Trial Profile
Apatinib for Advanced Recurrent Cervical Cancer Cooperative Group
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jun 2020
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Cervical cancer; Uterine cancer
- Focus Therapeutic Use
- Acronyms AARCA
- 04 May 2020 Status changed from recruiting to completed.
- 01 Aug 2017 New trial record